一品红：控股股东拟无偿转让Arthrosi 9.07%股权支持发展

Core Viewpoint - The company has received a commitment from its controlling shareholder, Guangrun Group, to support its development by transferring a 9.07% stake in Arthrosi, valued at $383 million post-Series E funding, to the company without any conditions or compensation [1] Group 1 - The board of directors approved the proposal regarding the support commitment from the controlling shareholder and the related party transaction [1] - The transaction is related to the acquisition of Arthrosi and the company's innovative gout drug, Deutepatide, in the Greater China market and for priority global supply [1] - The related party transaction has been exempted from requiring shareholder meeting approval, with related directors abstaining from the vote [1]